Key facts
- This page summarizes Cormorant Asset Management, LP's Form 4 filing for Immuneering Corp (IMRX).
- 8 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Apr 2024, 17:37.
Cormorant Asset Management, LP - 01 Apr 2024 Form 4 Insider Report for Immuneering Corp (IMRX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- IMRX
- Reported as of
- 01 Apr 2024
- Net transaction value
- -$1,160,181
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2024, 17:37:04 UTC
- Prior SEC filing
- 18 Mar 2024
- Next SEC filing
- 22 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cormorant Asset Management, LP filed Form 4 for Immuneering Corp (IMRX) on 03 Apr 2024.
Change
- Previous filing in this sequence was filed on 18 Mar 2024.
- Current net transaction value: -$1,160,181.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $307
- Shares
- -100
- Change %
- -0%
- Price
- $3.07
- Shares after
- 3,295,173
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F2
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $920
- Shares
- -300
- Change %
- -0.01%
- Price
- $3.06
- Shares after
- 3,294,873
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F3
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $305
- Shares
- -100
- Change %
- -0%
- Price
- $3.05
- Shares after
- 3,294,773
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F4
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $1,818
- Shares
- -600
- Change %
- -0.02%
- Price
- $3.03
- Shares after
- 3,294,173
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F5
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $30.1
- Shares
- -10
- Change %
- -0%
- Price
- $3.01
- Shares after
- 3,294,163
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F6
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $29.8
- Shares
- -10
- Change %
- -0%
- Price
- $2.98
- Shares after
- 3,294,153
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F7
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $832
- Shares
- -280
- Change %
- -0.01%
- Price
- $2.97
- Shares after
- 3,293,873
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F8
IMRX
transaction
Class A Common Stock
Sale
- Transaction value
- $1,155,940
- Shares
- -398,600
- Change %
- -12%
- Price
- $2.90*
- Shares after
- 2,895,273
- Date
- 01 Apr 2024
- Ownership
- See Footnote
- Footnotes
- F1, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Cormorant Asset Management, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 9 footnotes
Footnote F1
Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund") and Cormorant Private Healthcare Fund III, LP ("Fund III"). Cormorant Global Healthcare GP, LLC ("GP LLC") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
Footnote F2
Represents (i) 1,087,655 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,518 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F3
Represents (i) 1,087,556 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,317 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F4
Represents (i) 1,087,523 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,207,250 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F5
Represents (i) 1,087,325 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,848 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F6
Represents (i) 1,087,322 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,841 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F7
Represents (i) 1,087,319 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,834 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F8
Represents (i) 1,086,227 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 2,206,646 shares of Class A Common Stock beneficially owned by Fund III.
Footnote F9
Represents (i) 955,689 shares of Class A Common Stock beneficially owned by the Master Fund and (ii) 1,939,584 shares of Class A Common Stock beneficially owned by Fund III.